Piramal Pharma Ltd

Piramal Pharma Other Announcement

Piramal Pharma Limited informed exchanges that Niche99 has independently assigned it an ESG rating of 67.1 (ESG Band: Leader), without any company engagement.

Piramal Pharma Business Update

Piramal Pharma reported that the US FDA issued a Form-483 with 7 observations following a GMP inspection of its Morpeth, UK facility.

Piramal Pharma Other Announcement

Piramal Pharma Limited received an improved ESG rating of 65 from NSE Sustainability Ratings and Analytics. The rating was assigned voluntarily based on public disclosures.

Piramal Pharma Share Pledge

Deutsche Bank AG, acting as security agent, has disclosed the re-creation of a pledge over 98.4 million shares of Piramal Pharma Limited by the borrower.

Piramal Pharma Business Update

Piramal Pharma Limited released its Sustainability Report for FY2025-26, detailing the company's ESG performance across key pillars, including business resilience and operational sustainability.

Piramal Pharma Merger & Restructuring Worth ₹76 Cr

Piramal Pharma acquired an additional 40.67% stake in Yapan Bio for ₹76 Crore. This transaction increases its total holding to 74%, making Yapan Bio a subsidiary.

Value

₹76.00 Cr

Piramal Pharma Share Pledge

Deutsche Bank AG released 98,400,000 pledged equity shares of Piramal Pharma Limited, representing a 7.39% stake. The bank continues to hold 10.54% under pledge.

Piramal Pharma Merger & Restructuring

Piramal Pharma exercised a call option to acquire an additional 41% stake in Yapan Bio, becoming its majority shareholder with a 74% stake.

Piramal Pharma Business Update

Piramal Pharma has resumed operations at its Ahmedabad facility following the recent temporary suspension due to heavy rainfall. Operations are substantially restored with no material financial impact.

Piramal Pharma Annual General Meeting

Piramal Pharma Limited concluded its 6th Annual General Meeting, where shareholders approved all resolutions, including director re-appointments, auditor remuneration, and NCD issuance authority.

Piramal Pharma Investor Presentation: Key Takeaways

Piramal Pharma started FY27 with 17% revenue growth and 72% EBITDA expansion. Momentum was driven by CDMO recovery and power brands.

Piramal Pharma Results Update

Piramal Pharma Limited reported a consolidated revenue of ₹2,270 Crore for Q1 FY27, marking a 17% YoY increase. EBITDA for the quarter rose by 72% to ₹285 Crore.

Value

₹2,270 Cr

Piramal Pharma Q1 FY27 Results: Net Loss of ₹69.4 Cr, Loss Narrows

Piramal Pharma Ltd reported revenue from operations of ₹2,270 Cr (+17.4% YoY) and a net loss of ₹69.4 Cr for Q1 FY27.

Key figure

Net loss ₹69.4 Cr

Piramal Pharma Employee Stock Options

Piramal Pharma Limited announced the grant of 56,36,436 stock options to eligible employees under its Plan 2022. The options have an exercise price of Rs. 10 per share.

Piramal Pharma Adverse Business Impact

Piramal Pharma has temporarily suspended operations at its Ahmedabad facilities due to severe rainfall and flooding. The impact is currently under evaluation, with assets adequately insured.

Piramal Pharma Other Announcement

Piramal Pharma Ltd has submitted its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulations.

Piramal Pharma Board Meeting Date

Piramal Pharma Ltd scheduled a Board Meeting for July 29, 2026. The board will consider and approve the unaudited financial results for the quarter ended June 30, 2026.

Piramal Pharma Regulatory Approval

Piramal Pharma disclosed that the US FDA has successfully completed its inspection of the Sellersville manufacturing facility. The clearance affirms compliance and operational continuity.